Browse EX-10 agreements

STOCKHOLDERS AGREEMENT

THIS STOCKHOLDERS’ AGREEMENT (this “Agreement”) is made and entered into as of June 4, 2026, by and between (a) Applied Aerospace & Defense, Inc., a Delaware corporation (the “Company”), and (b) AA&D Holdings, LP, a Delaware limited partnership (“Greenbriar”). This Agreement shall become effective (the “Effective Date”) upon the closing of the Company’s proposed initial public offering (the “IPO”) of shares of its Common Stock (as defined below).

WHEREAS, as of the date hereof, Greenbriar Beneficially Owns (as defined below) a majority of the equity interests in the Company;

WHEREAS, Greenbriar is contemplating causing the Company to effect an IPO;

WHEREAS, Greenbriar currently has the authority to appoint all Directors (as defined below) of the Company; and

WHEREAS, in consideration of Greenbriar agreeing to undertake the IPO, the Company has agreed to permit Greenbriar to nominate Directors to the board of directors of the Company (the “Board”) following the Effective Date on the terms and conditions set forth herein.

…

Exhibit 10.1

EXHIBIT F

FORM OF LOCK-UP AGREEMENT

_________, 2026

	Re:	Business Combination Agreement, dated as of June 4, 2026 (the “Agreement”), among Bio Green Med Solution, Inc. (“Parent”), Future NRG Sdn. Bhd. (the “Company”) and the Selling Shareholders signatory thereto (each, a “Selling Shareholder” and, collectively, the “Selling Shareholders”)

Ladies and Gentlemen:

…

Exhibit 10.1

SECURITIES PURCHASE AGREEMENT

THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of May 29, 2026 (the “Effective Date”), is entered into between Biomerica, Inc., a Delaware corporation (the “Seller”), and each of the persons listed on Exhibit A hereto (each, a “Buyer” and collectively, the “Buyers”).

WHEREAS, Seller owns 78,750 shares of common stock representing approximately 6% of the issued and outstanding shares (the “Shares”), of Diagnosis S.A., a medical products producer and distributor headquartered in Białystok, Poland (the “Company”); and

WHEREAS, Seller wishes to sell to the Buyers, and each Buyer wishes to purchase from Seller, the Shares, subject to the terms and conditions set forth herein;

…

RESTRICTED STOCK AWARD AGREEMENT UNDER THE CRISPR THERAPEUTICS AG

2026 STOCK OPTION AND INCENTIVE PLAN

Name of Grantee:

No. of Restricted Shares:

Grant Date:

Pursuant to the CRISPR Therapeutics AG 2026 Stock Option and Incentive Plan as amended and in effect from time to time (the “Plan”), CRISPR Therapeutics AG (the “Company”) hereby grants an award of the number of Restricted Shares listed above (a “Award”) to the Grantee named above. Upon acceptance of this Award, the Grantee shall receive the number of common shares specified above (“Restricted Shares”), nominal value CHF 0.03 per share of the Company (each a “Common Share” and collectively, the “Common Shares”), subject to the restrictions and conditions set forth herein and in the Plan. The Company acknowledges the receipt from the Grantee of consideration with respect to the nominal value of the Common Shares in the form of cash, past or future services rendered to the Company by the Grantee or such other form of consideration as is acceptable to the Administrator.

…

RESTRICTED STOCK UNIT AWARD AGREEMENT FOR COMPANY EMPLOYEES UNDER THE CRISPR THERAPEUTICS AG 2026 STOCK OPTION AND INCENTIVE PLAN

Name of Grantee:
No. of Restricted Stock Units:
Grant Date:

Pursuant to the CRISPR Therapeutics AG 2026 Stock Option and Incentive Plan as amended and in effect from time to time (the “Plan”), CRISPR Therapeutics AG (the “Company”) hereby grants an award of the number of Restricted Stock Units listed above (an “Award”) to the Grantee named above. Each Restricted Stock Unit shall relate to one common share, nominal value CHF 0.03 per share of the Company (each a “Common Share” and collectively, the “Common Shares”).

…

RESTRICTED STOCK UNIT AWARD AGREEMENT FOR NON-EMPLOYEE DIRECTORS UNDER THE CRISPR THERAPEUTICS AG

2026 STOCK OPTION AND INCENTIVE PLAN

Name of Grantee:
No. of Restricted Stock Units:
Grant Date:

Pursuant to the CRISPR Therapeutics AG 2026 Stock Option and Incentive Plan as amended and in effect from time to time (the “Plan”), CRISPR Therapeutics AG (the “Company”) hereby grants an award of the number of Restricted Stock Units listed above (an “Award”) to the Grantee named above. Each Restricted Stock Unit shall relate to one common share, nominal value CHF 0.03 per share of the Company (each a “Common Share” and collectively, the “Common Shares”).

…

INCENTIVE STOCK OPTION AGREEMENT UNDER THE CRISPR THERAPEUTICS AG

2026 STOCK OPTION AND INCENTIVE PLAN

Name of Optionee:
No. of Option Shares:
Option Exercise Price per Common Share:	$
Grant Date:
Expiration Date:

Pursuant to the CRISPR Therapeutics AG 2026 Stock Option and Incentive Plan as amended and in effect from time to time (the “Plan”), CRISPR Therapeutics AG (the “Company”) hereby grants to the Optionee named above an option (the “Stock Option”) to purchase on or prior to the Expiration Date specified above all or part of the number of common shares specified above (the “Option Shares”), nominal value CHF 0.03 per share of the Company (each a “Common Share” and collectively, the “Common Shares”), at the Option Exercise Price per Common Share specified above subject to the terms and conditions set forth herein and in the Plan.

…

NON-QUALIFIED STOCK OPTION AGREEMENT FOR COMPANY EMPLOYEES UNDER THE CRISPR THERAPEUTICS AG

2026 STOCK OPTION AND INCENTIVE PLAN

Name of Optionee:
No. of Option Shares:
Option Exercise Price per Common Share:	$
Grant Date:
Expiration Date:

Pursuant to the CRISPR Therapeutics AG 2026 Stock Option and Incentive Plan as amended and in effect from time to time (the “Plan”), CRISPR Therapeutics AG (the “Company”) hereby grants to the Optionee named above an option (the “Stock Option”) to purchase on or prior to the Expiration Date specified above all or part of the number of common shares specified above (the “Option Shares”), nominal value CHF 0.03 per share of the Company (each a “Common Share” and collectively, the “Common Shares”), at the Option Exercise Price per Common Share specified above subject to the terms and conditions set forth herein and in the Plan. This Stock Option is not intended to be an “incentive stock option” under Section 422 of the US Tax Code.

…

NON-QUALIFIED STOCK OPTION AGREEMENT FOR NON-EMPLOYEE DIRECTORS UNDER THE CRISPR THERAPEUTICS AG

2026 STOCK OPTION AND INCENTIVE PLAN

Name of Optionee:
No. of Option Shares:
Option Exercise Price per Common Share:	$
Grant Date:
Expiration Date:

Pursuant to the CRISPR Therapeutics AG 2026 Stock Option and Incentive Plan as amended and in effect from time to time (the “Plan”), CRISPR Therapeutics AG (the “Company”) hereby grants to the Optionee named above, who is a member of the Board of the Company but is not an employee of the Company, an option (the “Stock Option”) to purchase on or prior to the Expiration Date specified above all or part of the number of common shares specified above (the “Option Shares”), nominal value CHF 0.03 per share of the Company (each a “Common Share” and collectively, the “Common Shares”), at the Option Exercise Price per Common Share specified above subject to the terms and conditions set forth herein and in the Plan. This Stock Option is not intended to be an “incentive stock option” und

…

CRISPR THERAPEUTICS AG

2026 STOCK OPTION AND INCENTIVE PLAN

SECTION 1.

GENERAL PURPOSE OF THE PLAN; DEFINITIONS

The name of the plan is the CRISPR Therapeutics AG 2026 Stock Option and Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of CRISPR Therapeutics AG (the “Company”) and its Affiliates upon whose judgment, initiative and efforts the Company largely depends for the successful conduct of its business to acquire a proprietary interest in the Company. It is anticipated that providing such persons with a direct stake in the Company’s welfare will assure a closer identification of their interests with those of the Company and its shareholders, thereby stimulating their efforts on the Company’s behalf and strengthening their desire to remain with the Company.

The following capitalized terms used herein or used in any Award Certificate shall have the following meanings:

…

ABACUS GLOBAL MANAGEMENT, INC.

2026 LONG-TERM EQUITY

INCENTIVE PLAN

1.PURPOSE

The purpose of the ABACUS GLOBAL MANAGEMENT, INC. 2026 LONG-TERM EQUITY INCENTIVE PLAN (the “Plan”) is to provide a means through which Abacus Global Management, Inc., a Delaware corporation (“Company”), and its Affiliates may attract able individuals to enter the employ or to serve as Directors or Consultants of the Company and any of its Affiliates and to provide a means whereby those individuals upon whom the responsibilities of the successful administration and management of the Company and its Affiliates rest, and whose present and potential contributions to the Company and its Affiliates are of importance, can acquire and maintain ownership of the Company’s Common Stock, thereby strengthening their concern for the welfare of the Company and its Affiliates. A further purpose of the Plan is to provide such individuals with additional incentive and reward opportunities designed to enhance the profitable growth of the Company and its Affiliates. Accordingly, the Plan provides for granting Incentive St

…

Amendment No 1.

to the

W&T Offshore, Inc. 2023 Incentive Compensation Plan

This Amendment No. 1 to the W&T Offshore, Inc. 2023 Incentive Compensation Plan (the “Plan”) was approved and recommended to the shareholders by the Board of Directors of W&T Offshore, Inc. (the “Company”) on April 13, 2026, subject to the approval by the shareholders of the Company, which was obtained on June 3, 2026. Accordingly, the Plan is hereby amended, effective as of June 3, 2026, as follows:

1.	Section 4.1 of the Plan is hereby amended and restated in its entirety with the following:

…